Can You Actually Get DNA From Urine for Testing?

Urine contains usable DNA, and the amount of clinical testing already built around that fact may surprise you. Two main forms of DNA can be recovered from a urine sample: cells shed from the lining of the urinary tract (and the DNA inside them) and cell-free DNA, which consists of tiny fragments floating in the liquid portion. That cell-free fraction is the more scientifically exciting of the two, because some of it doesn’t even originate in the urinary system. Fragments from dying cells elsewhere in the body can cross the kidney’s filtration barrier, land in urine, and carry molecular signatures of diseases happening far from the bladder. The catch is that urine is a harsh environment for DNA, and getting reliable results requires careful handling at every step.

Where the DNA in Urine Comes From

When you provide a urine sample, it carries two distinct pools of genetic material. The first is cellular DNA, trapped inside epithelial cells that naturally slough off the bladder, ureters, and urethra. Spin a urine sample in a centrifuge, and these cells settle into a pellet at the bottom. The DNA you extract from that pellet is relatively intact and abundant, which is why it has long been the workhorse for routine urine-based genetic tests like STI screening.

The second pool is cell-free DNA (cfDNA), which floats in the liquid supernatant above the pellet. This fraction comes from multiple sources. In healthy people, the strongest signals trace back to urinary epithelium, kidney tissue, and immune cells like neutrophils.¹ But a portion of urinary cfDNA actually originates outside the urinary tract entirely. When cells anywhere in the body die through normal turnover or disease, their DNA breaks into fragments that enter the bloodstream. Some of those fragments, typically around 150 to 200 base pairs long, are small enough to pass through the kidney’s glomerular filter and end up in urine.² This “transrenal” DNA is what makes urine potentially useful for detecting conditions that have nothing to do with the bladder or kidneys.

Methods exist to isolate each fraction separately, which matters because cfDNA and cellular DNA can tell different stories about what’s going on in the body.³ For bladder cancer screening, for instance, the DNA shed directly from tumor cells in the sediment and the free-floating tumor DNA in the supernatant can yield complementary information.

Cancer Detection Through Urinary DNA

Bladder cancer is the most natural fit for urine-based DNA testing, since tumor cells sit in direct contact with urine. One study using deep sequencing of urinary DNA detected bladder cancer with roughly 87% sensitivity and 85% specificity across two independent groups of patients presenting with blood in their urine. Detection was best for higher-grade tumors, reaching about 97% for the most aggressive grade, and lower for early-stage disease at around 71%.⁴ For patients already being monitored after a prior bladder cancer diagnosis, a positive urine mutation test even in the absence of visible disease was linked to a roughly 2.6-fold higher risk of future recurrence, suggesting urine DNA could serve as an early warning system.

An interesting wrinkle is which fraction of the urine sample works better. One analysis found that the cell-free supernatant actually outperformed the cell sediment for detecting early-stage, superficial bladder tumors, with sensitivity of about 84% versus 67%.⁵ The explanation likely involves the way superficial tumors release DNA into the urine stream without shedding large clumps of intact cells. A separate study comparing a specific mutation (TERT promoter) across the two fractions found that sediment DNA caught mutations more often overall, but cfDNA actually performed better in samples with a lot of immune cells, which can dilute the cancer signal in the pellet.⁶ The practical takeaway is that neither fraction is universally superior; which one to test depends on the clinical context.

What’s more remarkable is that urinary DNA testing is expanding well beyond cancers of the urinary tract. For cancers originating in other organs, the transrenal pathway means tumor DNA fragments can still end up in urine. A systematic review pooling data across non-urothelial cancers found that urinary cfDNA achieved about 80% sensitivity and 96% specificity overall.⁷ Sensitivity for specific cancer types using urine cfDNA has been reported as comparable to blood-based liquid biopsy for many cancers.⁸

For lung cancer patients who have developed resistance to targeted therapy, urine testing detected specific drug-resistance mutations in some patients who couldn’t undergo tissue biopsy or whose tissue results were inconclusive, boosting the overall detection rate by about 7% compared to tissue testing alone.⁹ For liver cancer, a panel of urinary cfDNA methylation markers combined with a standard blood protein test achieved an area under the curve of about 0.91 for distinguishing liver cancer from controls, significantly outperforming the blood test on its own.¹⁰ And for prostate cancer, researchers have found distinct methylation patterns in urinary cfDNA that help distinguish patients with metastatic disease from those without spread, though the number of differentially methylated regions in urine was smaller than what could be detected in blood plasma.¹¹

Infectious Disease Testing

The most established use of urine DNA in everyday medicine is screening for sexually transmitted infections. Testing first-void urine for chlamydia and gonorrhea has been standard practice for years, and it relies on amplifying the pathogen’s DNA directly from the sample. Multiple automated platforms can reliably detect these organisms in urine.¹² Even in asymptomatic individuals, DNA amplification methods in urine have outperformed older antigen-detection approaches, with one early comparison finding sensitivities above 90% for the best DNA-based assay versus under 40% for antigen testing.¹³ This matters because urine collection is far less invasive than a urethral swab, which has made broad STI screening programs practical in a way they never could have been otherwise.

Tuberculosis diagnosis is a newer and more challenging frontier. TB bacteria primarily infect the lungs, so the traditional diagnostic sample is sputum. But many patients, including young children, people with HIV, and those too sick to cough productively, can’t easily provide a sputum sample. The discovery that TB DNA fragments cross the kidney barrier and appear in urine opened an alternative route. In a South African clinical study, a urine cfDNA assay for TB reached about 84% sensitivity and 100% specificity when compared against sputum-based molecular testing.¹⁴ A study in Peru found patient-level sensitivity of about 73%, with the best results in patients with higher bacterial loads and the lowest sensitivity in smear-negative cases.¹⁵ Notably, one study found that an extraction method designed for transrenal DNA picked up TB in seven out of ten samples that a standard molecular platform had missed entirely.¹⁶ The technology isn’t yet a replacement for sputum testing, but in settings where sputum isn’t available, urine-based TB detection could fill a real gap.

Transplant Monitoring

When someone receives a kidney transplant, one of the biggest ongoing concerns is whether the immune system is quietly rejecting the new organ. Currently, that question is answered definitively only by biopsy, an invasive procedure with its own risks. Donor-derived cell-free DNA offers a different approach: if the transplanted kidney is under immune attack, its cells die faster, releasing more of the donor’s DNA into the recipient’s blood and urine. Elevated donor-derived cfDNA in plasma above a threshold of about 0.5% has been independently associated with antibody-mediated rejection, with one study finding roughly a 22-fold increase in the odds of that diagnosis compared to no rejection.¹⁷ The same study found that combining donor-derived cfDNA with a urinary immune marker called CXCL10 could help distinguish between different types of rejection, since each biomarker correlated with different patterns of tissue damage. This kind of non-invasive surveillance could eventually reduce the number of biopsies transplant recipients need.

Why Prenatal Testing from Urine Hasn’t Worked Out

Given that fetal DNA circulates in a pregnant person’s blood and some of that DNA crosses the kidneys, it would seem logical that maternal urine could be used for non-invasive prenatal testing. Researchers have tried. The results have been disappointing. One study using highly sensitive methods detected Y-chromosome sequences (indicating a male fetus) in only about a third of urine samples from women carrying boys, and using a different genetic target the detection rate dropped to around 6%.¹⁸ Another study failed to detect fetal Y-chromosome DNA in any of 20 maternal urine samples, even though the same fetal DNA was readily detected in those women’s blood plasma.¹⁹

The problem appears to be concentration and degradation. Fetal cfDNA makes up a small minority of the total cfDNA in maternal blood to begin with, and after crossing the kidney barrier, whatever remains is further diluted in a large volume of urine and subjected to enzymes that chew up DNA. Blood-based non-invasive prenatal testing, which is now widely used and highly accurate, has made the question somewhat moot for clinical purposes. But the failure of urine-based prenatal testing is a useful reminder that not every type of transrenal DNA is present in quantities high enough to be practical.

Handling and Preservation Make or Break the Results

Urine is not a friendly environment for DNA. It contains enzymes called DNases that actively degrade free-floating fragments, and bacteria in the sample can multiply at room temperature and contaminate the genetic signal. How a sample is collected, stored, and processed has an outsized effect on whether the DNA in it remains usable.

Left at room temperature in a plain collection tube, urinary cfDNA degrades rapidly. But specialized preservative tubes can maintain the original DNA profile for up to seven days at temperatures ranging from near-freezing to body temperature, while also preventing bacterial overgrowth.²⁰ A separate study confirmed that purpose-built urine collection tubes preserved the proportion and integrity of cfDNA for up to a week at ambient temperature, while samples in standard tubes showed obvious degradation, with the representation of specific gene variants drifting by nearly four-fold.²¹

Beyond degradation, there’s meaningful person-to-person and day-to-day variability. One study found that cfDNA concentrations from the same individuals varied substantially across different days, and that female samples tended to contain more cfDNA than male samples.²² The choice of extraction kit also matters, as the same study found that different commercial kits yielded different amounts of cfDNA from identical samples. For bacterial DNA in urine, a common obstacle is the presence of crystals and PCR inhibitors that can block amplification. Pre-treating urine to dissolve crystals before centrifugation has been shown to improve bacterial DNA recovery and reduce inhibition.²³

These pre-analytical variables explain why urine DNA testing requires more standardization than blood-based testing before it can be widely deployed in routine clinical practice. A test that works beautifully in a research lab with immediate sample processing and specialized equipment can fail in a community clinic where samples sit on a counter for hours before shipping.

How It Compares to Blood-Based Liquid Biopsy

Blood draws are the current gold standard for liquid biopsy, meaning any test that looks for circulating tumor DNA or other cell-free markers in body fluids rather than tissue. Urine has some genuine advantages over blood. Collection is entirely non-invasive, requires no trained phlebotomist, and can be done at home. For cancers of the urinary tract, urine puts you closer to the source: tumor DNA is more concentrated in urine than in blood for bladder and kidney cancers simply because the tumors are bathed in it.

For cancers outside the urinary tract, the picture is more mixed. The transrenal DNA in urine is more fragmented and dilute than cfDNA in blood plasma, which makes detection harder and generally requires more sensitive assays. Recent reviews suggest that for many non-urological cancer types, urinary cfDNA sensitivity is approaching what blood achieves, but the comparison depends heavily on the specific cancer, the assay used, and how the sample was handled.⁸ In prostate cancer, for example, plasma cfDNA still yielded more differentially methylated regions than urinary cfDNA, suggesting blood remains the richer source of epigenetic information for that disease.¹¹

Where urine stands to add the most value may not be as a replacement for blood but as a complement. In lung cancer patients who couldn’t undergo tissue biopsy, urine testing picked up actionable mutations that would otherwise have been missed.⁹ And for conditions like TB in resource-limited settings where blood processing infrastructure may be scarce, a urine test that can be preserved for days at ambient temperature is worth something even if its sensitivity is slightly lower than a blood-based approach.

What’s Approved and What’s Still Experimental

It’s worth separating what you can already get from your doctor from what remains in the research pipeline. Urine-based nucleic acid amplification tests for chlamydia and gonorrhea are FDA-cleared, widely available, and used millions of times a year. Several FDA-approved urine biomarker tests for bladder cancer also exist, including protein-based assays like NMP22 and BTA, and the FISH-based UroVysion test, though these test for proteins or chromosomal abnormalities rather than sequencing DNA directly.²⁴

Most of the DNA sequencing-based approaches described in this article, such as targeted deep sequencing for bladder cancer mutations, methylation panels for liver cancer, and TB transrenal DNA assays, are still in clinical research or are offered through specialty labs and clinical trials rather than as routine clinical tests. The technology clearly works; the barriers to wider adoption are standardization, cost, and regulatory clearance. Specialized library preparation methods designed to recover very short, degraded cfDNA fragments have been key to making some of these assays feasible at all.²⁵ As sample preservation improves and assay costs come down, more of these tests are likely to move from research into clinical practice.

Forensic and Paternity Applications

Outside of medicine, people sometimes ask whether urine left at a crime scene or provided for a drug test could yield a DNA profile for identification. The answer is technically yes, but it depends on the sample. Urine that contains enough shed epithelial cells can provide a full genetic profile through standard forensic methods. The cell pellet from a fresh, uncontaminated sample often has enough intact cellular DNA for typing. The cell-free fraction, however, is usually too fragmented and too low in concentration for standard forensic short tandem repeat profiling, which requires somewhat longer stretches of intact DNA than the 150-to-200 base pair fragments typical of transrenal cfDNA.

In practice, forensic success with urine samples is inconsistent. A fresh sample with visible sediment is much more likely to yield a usable profile than a dilute, old, or degraded one. Urine found at a scene that has dried or been exposed to heat or sunlight may have lost most of its cellular DNA to degradation. For paternity or identity testing, urine is not a preferred sample type precisely because of this unreliability. A cheek swab provides orders of magnitude more high-quality DNA with none of the preservation headaches. But when urine is the only available sample, modern extraction and amplification techniques can sometimes recover enough for identification.

Urine Collection Timing and Type

If you’ve been asked to provide urine for DNA-based testing, you might wonder whether it matters when and how you collect it. For STI testing, first-void urine (the initial stream rather than midstream) is preferred because it washes out the highest concentration of pathogen DNA from the urethra. For cell-free DNA analysis targeting cancer or other diseases, the picture is less settled. Some researchers use first-morning voids on the theory that overnight concentration in the bladder increases the amount of DNA per milliliter. Others have found that cfDNA yields are reasonably consistent regardless of collection method, with one study reporting average cfDNA concentrations of roughly 19 to 20 nanograms per milliliter whether the urine was processed by centrifugation or filtration.²⁶

What does appear to matter more than timing is how quickly the sample reaches a preservative or gets processed. As discussed earlier, unpreserved urine degrades within hours at room temperature. If you’re collecting a sample at home for a test that looks at cfDNA, following the lab’s instructions about which tube to use and how to store it before shipping is more important than agonizing over whether to collect the first or second void of the day.